NCT07100730
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07100730
Title Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma (IPAX BrIGHT)
Acronym IPAX BrIGHT
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Telix Pharmaceuticals (Innovations) Pty Limited
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS


No variant requirements are available.